Differences in 18F-FDG Uptake and Expression of Glucose Transporter Between 2 Distinct Subtypes of Mass-Forming Intrahepatic Cholangiocarcinomas.

PURPOSE Recently, intrahepatic cholangiocarcinoma (iCCA) has been classified into small duct cholangiocarcinoma (SDC) and large duct cholangiocarcinoma (LDC) according to the origin of the biliary tree. Although the usefulness of F-FDG PET/CT in iCCA is well known, there are no reports evaluating differences in accumulation of F-FDG according to the recently described iCCA subtypes. The aim of this study was therefore to assess F-FDG accumulation and the expression of glucose transporters in SDC and LDC. METHODS Our institutional review board approved this retrospective study and waived the requirement for informed consent. Fourteen consecutive surgically resected mass-forming iCCA (7 SDCs, 23 ± 6.7 mm; 7 LDCs, 44 ± 26 mm) were enrolled. The SUVmax on F-FDG PET/CT and the expression of glucose transporter 1 (Glut-1), Glut-2, hexokinase 2 (HK2), and glucose-6-phosphatase by immunohistochemistry were evaluated and compared between SDC and LDC. RESULTS The SUVmax in SDC was significantly lower than that in LDC (3.2 ± 0.8 vs 7.6 ± 3.2, P < 0.01). The staining scores of Glut-1 and HK2 were significantly lower in SDC than in LDC (0 vs 3 ± 1.4, P = 0.0034; 1.6 ± 1.1 vs 3.4 ± 1.1, P = 0.014, respectively). Expression levels of Glut-2 and glucose-6-phosphatase were variable and did not show a significant difference between SDC and LDC. Overall survival was significantly worse in LDC than in SDC (P = 0.01). CONCLUSIONS F-FDG accumulation and Glut-1 and HK2 expression were significantly higher in LDC than in SDC. A low-glycolytic feature may be one of the characteristic findings of SDC.

[1]  O. Matsui,et al.  Peribiliary glands: development, dysfunction, related conditions and imaging findings , 2019, Abdominal Radiology.

[2]  T. Higashi,et al.  Reappraisal of Prognostic Impact of Tumor SUVmax by 18F-FDG-PET/CT in Intrahepatic Cholangiocarcinoma , 2019, World Journal of Surgery.

[3]  K. Ahn,et al.  Genetic features associated with 18F-FDG uptake in intrahepatic cholangiocarcinoma , 2019, Annals of surgical treatment and research.

[4]  Richard K G Do,et al.  Intrahepatic Cholangiocarcinomas Have Histologically and Immunophenotypically Distinct Small and Large Duct Patterns , 2018, The American journal of surgical pathology.

[5]  Yoshiko Takahashi,et al.  Intrahepatic Cholangiolocellular and Cholangiocellular Carcinoma - Differences in the 18F-FDG PET/CT Findings , 2017, Internal medicine.

[6]  O. Matsui,et al.  Dynamic CT findings of cholangiolocellular carcinoma: correlation with angiography-assisted CT and histopathology , 2017, Abdominal Radiology.

[7]  I. Yoo,et al.  The Role of F-18 FDG PET/CT in Intrahepatic Cholangiocarcinoma , 2017, Nuclear Medicine and Molecular Imaging.

[8]  K. Boberg,et al.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) , 2016, Nature Reviews Gastroenterology &Hepatology.

[9]  Y. Nakanuma,et al.  Pathologic classification of cholangiocarcinoma: New concepts. , 2015, Best practice & research. Clinical gastroenterology.

[10]  Y. Oda,et al.  Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type , 2015, Journal of hepato-biliary-pancreatic sciences.

[11]  H. Honda,et al.  Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma. , 2014, Human pathology.

[12]  L. Giovanella,et al.  Diagnostic Accuracy of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in the Evaluation of the Primary Tumor in Patients with Cholangiocarcinoma: A Meta-Analysis , 2014, BioMed Research International.

[13]  C. Panje,et al.  Role of 18F-FDG PET/CT Imaging in Intrahepatic Cholangiocarcinoma , 2014, Clinical nuclear medicine.

[14]  Masakazu Yamamoto,et al.  Long-term Survival of Patients with Cholangiolocellular Carcinoma After Curative Hepatectomy , 2014, Annals of Surgical Oncology.

[15]  G. Cheon,et al.  Implication of Lymph Node Metastasis Detected on 18F-FDG PET/CT for Surgical Planning in Patients With Peripheral Intrahepatic Cholangiocarcinoma , 2014, Clinical nuclear medicine.

[16]  J. Xu,et al.  Intrahepatic cholangiocarcinomas in cirrhosis are hypervascular in comparison with those in normal livers , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[17]  T. Roskams,et al.  Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes , 2012, Hepatology.

[18]  R. Subramaniam,et al.  Value of PET/CT in the management of primary hepatobiliary tumors, part 2. , 2011, AJR. American journal of roentgenology.

[19]  Masakazu Yamamoto,et al.  Mass‐forming intrahepatic cholangiocarcinoma with marked enhancement on arterial‐phase computed tomography reflects favorable surgical outcomes , 2011, Journal of surgical oncology.

[20]  M. Aljiffry,et al.  Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. , 2009, World journal of gastroenterology.

[21]  K. Iwaisako,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. , 2008, Surgery.

[22]  T. Higuchi,et al.  Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]‐2‐fluro‐2‐deoxy‐d‐glucose positron emission tomography , 2008, Cancer science.

[23]  O. Matsui,et al.  A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: ‘bile ductular carcinoma’ , 2007, Histopathology.

[24]  M. Kadoya,et al.  Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression , 2006, Annals of nuclear medicine.

[25]  J. Lee,et al.  Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  J. H. Lim,et al.  Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. , 2003, AJR. American journal of roentgenology.

[27]  J. Lee,et al.  Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  M. Younes,et al.  Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. , 1996, Cancer research.

[29]  Kazutomo Inoue,et al.  Over-expression of facilitative glucose transporter genes in human cancer. , 1990, Biochemical and biophysical research communications.

[30]  G. Gores,et al.  Classification, diagnosis, and management of cholangiocarcinoma. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[31]  Y. Tsushima,et al.  Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma , 2008, Annals of nuclear medicine.

[32]  S. Fan,et al.  Intrahepatic Cholangiocarcinoma , 1997, World Journal of Surgery.